About Redbiotec
Redbiotec is a Healthcare company based in Schlieren (Switzerland) founded in 2006 by Corinne John. Multiprotein assemblies are developed as prophylactic vaccines against infectious diseases. Redbiotec has raised $1.87 million across 2 funding rounds from investors including Redalpine. Redbiotec offers products and services including Key Proteins, Genetic Materials, and BRISPR®tech. Its focus areas include Life Sciences, Oncology, Drugs and Pancreatic Cancer. Its legal entity is Redbiotec AG.
Company details
Redbiotec was founded in 2006 as a spin-off from ETH Zurich and operates as a privately held biopharmaceutical company based in Schlieren, Switzerland. Proprietary rePAX co-expression technology is utilized for generating multi-component virus-like particles and protein assemblies. A pipeline of prophylactic VLP vaccines targeting infectious diseases is being advanced, while customized biologics solutions are provided to select partners.
- Headquarters Schlieren, Switzerland
- Founders Corinne John
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website redbiotec.ch
- Social LinkedIn X
- Legal Name Redbiotec Ag
- Total Equity Funding$1.87M (USD)
in 2 rounds
- Latest Funding Round$1.45M (USD), Private Equity Round
Nov 2014
- Investors
Products & Services of Redbiotec
Redbiotec offers a comprehensive portfolio of products and services, including Key Proteins, Genetic Materials, and BRISPR®tech.
Proteins for therapeutic and industrial applications
Materials for genetic research and production
Platform for protein and genetic material development
Funding Insights of Redbiotec
Redbiotec has successfully raised a total of $1.87M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $1.45 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.87M
- Total Rounds 2
- Last Round Private Equity Round — $1.45M
- First Round $420,000
(Apr 2010)
- Investors Count 1
All 2 funding rounds of Redbiotec with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $1.45M | Private Equity Round | – | – | |
| Apr 2010 | $420,000 | Private Equity Round | – | – | – |
1 investors in total: 1 institutional.
Investors in Redbiotec
Redbiotec has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Redalpine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are directed toward ICT and health tech startups. | redalpine.com | Zurich, Switzerland |
Investor details for Redbiotec
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Redbiotec
2 people are tracked at Redbiotec (2 in leadership).
| Name | Role | Group |
|---|---|---|
Corinne John | Co-Founder | Leadership |
Christian Schaub | CEO And President, Chairman Of The Board Of Directors | Leadership |
Complete people profiles for Redbiotec
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Redbiotec
3 dated milestones of Redbiotec across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Redbiotec is founded.
- Funding First funding round of $420K.
- Funding Latest funding round, Private Equity Round, of $1.4M.
Web traffic of Redbiotec
The website of Redbiotec (redbiotec.ch) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 105.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Redbiotec
Complete news archive for Redbiotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Redbiotec
Redbiotec was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Redbiotec is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Redbiotec is a funded company, having raised a total of $1.87M across 2 funding rounds to date. The company's 1st funding round was a Private Equity Round of $420K, raised on Apr 2010.
Redbiotec was founded in 2006 as a spin-off from ETH Zurich and operates as a privately held biopharmaceutical company based in Schlieren, Switzerland. Proprietary rePAX co-expression technology is utilized for generating multi-component virus-like particles and protein assemblies. A pipeline of prophylactic VLP vaccines targeting infectious diseases is being advanced, while customized biologics solutions are provided to select partners.
Redbiotec offers Key Proteins, Genetic Materials, and BRISPR®tech.
Redbiotec has 1 investor. Key investors include Redalpine.
Redbiotec operates through Redbiotec Ag.